Nkarta, Inc.
Status: Publicly traded
Direct answer
Nkarta, Inc. is publicly traded on NASDAQ under the ticker NKTX.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and...
Can you invest in Nkarta, Inc.?
Yes. Nkarta, Inc. is publicly traded on NASDAQ under the ticker NKTX.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Nkarta, Inc.
Detailed equity research is provided by MarketSnap.